Effektivnost' primeneniya rabeprazola (Bereta) v lechenii bol'nykh gastroezofageal'noy reflyuksnoy bolezn'yu


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

The evaluation of the efficacy of rabeprazole (Bereta, Veropharm) in the treatment of gastroesophageal reflux disease (GERD) was performed. Twenty-five patients with GERD, including 15 patients with erosive reflux esophagitis (RE), have received rabeprazole at daily dose of 20 mg for 21 days. At the 14th day of treatment, heartburn was arrested in 100%, regurgitation - in 91.7%, belching air - in 76.5% of patients. At the 21st day of treatment, epithelialization of erosions was achieved in 100% of patients with erosive RE. Relief of symptoms was accompanied by a significant improvement in well-being and quality of life of patients.

Texto integral

Acesso é fechado

Sobre autores

D. Bordin

O. Yanova

V. Kim

Bibliografia

  1. Vakil N., van Zanden S.V., Kahrilas P., Dent J., Jones R.; Global Consensus Group. The Monreal Definition and Classification of Gastroesophageal Reflux Disease: A Global Evidence-Based Consensus. Am. J. Gastroenterol. 2006;101:1900-20.
  2. Van Pinxteren B., Numan M.E., Bonis P.A., Lau J., Numans M.E. Shortterm treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst. Rev. 2004;(4):CD002095.
  3. Holtmann G., Adam B., Liebregts T. Review article: the patient with gastro-oesophageal reflux disease-lifestyle advice and medication. Aliment. Pharmacol. Ther. 2004;20(Suppl. 8):24-7.
  4. Yamano H.O., Matsushita H.O., Yanagiwara S. Plasma concentration of rabeprazole after 8-week administration in gastroesophageal reflux disease patients and intragastric pH elevation. J. Gastroenterol. Hepatol. 2008; 23:534-40.
  5. Robinson M., Fitzgerald S., Hegedus R., Murthy A., Jokubaitis L.; FAST Trial Investigators. Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis. Aliment. Pharmacol. Ther. 2002;16:445-54.
  6. Miner P.J., Orr W., Filippone J., Jokubaitis L., Sloan S. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Am. J. Gastroenterol. 2002;97:1332-39.
  7. Swan S.K., Hoyumpa A.M., Merritt G.J. The pharmacokinetics of rabeprazole in health and disease. Aliment. Pharmacol. Ther. 1999;13(Suppl. 3):11-7.
  8. Новик А.А., Ионова Т.И. Руководство по исследованию качества жизни в медицине. СПб.; М., 2002.
  9. Lundell L.R., Dent J., Bennett J.R., Blum A.L., Armstrong D., Galmiche J.P., Johnson F., Hongo M., Richter J.E., Spechler S.J., Tytgat G.N., Wallin L. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999;45(2):172-80.
  10. Fock K.M., Teo E.K., Ang T.L., Chua T.S., Ng T.M., Tan Y.L. Rabeprazole vs esomeprazole in non-erosive gastro-esophageal reflux disease: a randomized, double-blind study in urban Asia. World J. Gastroenterol. 2005;11(20): 3091-98.
  11. Holtmann G., Bytzer P., Metz M., Loeffler V., Blum A.L. A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther. 2002;16(3):479-85.
  12. Camacho F., Perdomo C., Jokubaitis L., et al. Rabeprazole provides better heartburn relief compared to omeprazole in the first 3 days and 7 days of treatment. [abstract]. N.Y., 2000. P. 13-18.
  13. Fass R., Sifrim D. Management of heartburn not responding to proton pump inhibitors. Gut. 2009;58:295-309.
  14. Zerbib F., Roman S., Ropert A., des Varannes S.B., Pouderoux P., Chaput U., Mion F., Verin E., Galmiche J.P., Sifrim D. Esophageal pH-impedance monitoring and symptom an alysis in GERD: a study in patients off and on therapy. Am. J. Gastroenterol. 2006;101: 1956-63.
  15. Лазебник Л.Б., Бордин Д.С., Машарова А.А. и др. Факторы, влияющие на эффективность лечения ГЭРБ ингибиторами протонной помпы. Терапевтический архив. 2012; 2:16-21.
  16. Johanson J.F., Siddique R., Damiano A.M., Jokubaitis L., Murthy A., Bhattacharjya A. Rabeprazole improves health-related quality of life in patients with erosive gastroesophageal reflux disease. Dig. Dis. Sci. 2002;47(11): 2574-78.
  17. Johnson D.A., Riff R., Perdomo C., Jaskir J., Niecestro R., Hahne W. Rabeprazole: safety profile of a new proton pump inhibitor. Gastroenterology. 1999;116:209.
  18. Cloud M.L., Enas N., Humphries T.J., Bassion S. Rabeprazole in treatment of acid peptic disease. Results of three placebo-controlled dose-response clinical trails in duodenal ulcer, gastric ulcer and gastroesophageal reflux disease (GERD). Dig. Dis. Sci. 1998;43(5):993-1000.
  19. Humphries T.J., Hindi G., Fiocca R. Argyrophil ECL cell histology in the gastric corpus and antrum in 243 patients taking rabeprazole 10 mg or 20 mg or omeprazole 20 mg for one year. World Congress of Gastroenterology. Vienna, 1998. 111 p.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2015

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies